2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disorders
2016
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairment